生命科学资讯
生物技术与制药领域的最新动态
Lilly drops 3 pipeline drugs, including gene therapy, from $1B Prevail buyout
葛兰素史克新任CEO寻求20亿至40亿美元“显而易见”的交易机会。
GSK's new CEO looking for $2B to $4B deals 'hiding in plain sight'
美敦力加码收购以色列医疗设备公司CathWorks,交易金额高达5.85亿美元。
Medtronic steps up with up to $585M deal for Israeli devicemaker CathWorks
FDA要求雅培就Libre检查违规问题作出更好回应。
FDA demands better response from Abbott over Libre inspection violations
临床前干细胞生物科技公司PrimeGen选择SPAC方式登陆纳斯达克。
Preclinical stem cell biotech PrimeGen takes SPAC route to Nasdaq
Hims & Hers将通过其数字健康平台销售Grail的Galleri多癌血液检测服务。
Hims & Hers to sell Grail’s Galleri multi-cancer blood test via its digital health platform
NHS“FIT”肠癌检测减少不必要转诊,癌症病例数保持稳定。
NHS 'FIT' bowel cancer test reduced unnecessary referrals as cancer numbers remain stable
诺和诺德CEO“祝辉瑞好运”但继续寻求自有月度GLP-1药物
Novo's CEO 'wishes Pfizer luck' with Metsera drug, but still seeks own monthly GLP-1
安进在狼疮治疗上迈向救赎,胃癌候选药物却遇挫。
Amgen advances toward lupus redemption while gastric cancer candidate struggles
美国卫生与公众服务部启动1亿美元抗病毒药物奖,旨在开发广谱疗法。
HHS launches $100M antiviral prize to develop broad-spectrum therapies
NIH风波成焦点,主任承认疫苗与自闭症无关。
NIH turmoil takes center stage as director acknowledges no vaccine-autism link
辉瑞CEO宣布,在完成六项早期项目削减及44亿美元减值后,管线优化已基本完成。
Pfizer CEO says pipeline pruning is mostly finished after 6 more early-stage culls, $4.4B in impairment charges
新兴生物科技公司Exxel计划通过1300万美元IPO,在FAAH抑制剂领域寻求突破。
Fledgling biotech Exxel plans $13M IPO to succeed where other FAAH inhibitors have failed
FDA暗示将采取定制化策略,以“审慎引导”CAR-T疗法用于自身免疫性疾病治疗。
FDA signals tailored approach to ‘carefully shepherd’ CAR-T therapy for autoimmune diseases
查尔斯河将关闭细胞疗法CDMO基地,裁员20名员工。
Charles River to close cell therapy CDMO site, lay off 20 staffers
辉瑞每月投入100亿美元押注GLP-1药物,二期b阶段试验显示减肥效果具竞争力。
Pfizer's $10B monthly GLP-1 bet generates competitive weight loss in phase 2b
NMD罕见病试验失败,但借次要数据加速项目推进
NMD flunks rare disease trial but flexes secondary data to accelerate program
奎斯特推出多发性骨髓瘤残留病灶血液检测
Quest launches residual disease blood test for multiple myeloma
Mirum如何通过战略并购推动罕见病护理进步
How Mirum is Advancing Rare Disease Care Through Strategic M&A